The Quandt Lab brings together expertise in clinical care, immunology, and data scientists to understand endocrine disorders triggered by cancer immunotherapies and to advance early-intervention strategies for type 1 diabetes with the ultimate goal to prevent these disorders.

Dr. Quandt is also an executive leader of the Endocrine Clinical and Translational Research Center (ECTRC) and Biobank. The ECTRC and Biobank provides infrastructure for clinical and translational research and is available to partner with academic, investigator-initiated research as well as industry sponsored research. More information can be found here.

Our Mission

Improve outcomes for patients on cancer immunotherapy by predicting, preventing and optimizing treatment of endocrine immune-related adverse events (irAEs).

Preserve β-cell function in individuals at risk for or in the early stages of type 1 diabetes through innovative screening programs and FDA approved immunomodulatory therapy—most notably, teplizumab.

Bridge bench and bedside by building translational pipelines from mechanistic insights to personalized clinical care.

what we study

Endocrine Complications of Cancer Immunotherapy

We are pioneering the prediction of immune related adverse events (irAEs) using a multimodal approach that integrates clinical features, autoantibody profiles, genetic risk markers and immunophenotypes. We are considering approaches to closer monitoring of patients at risk for irAEs as well as treatments that can prevent or attenuate endocrine irAEs. The lab houses:

• Curated clinical databases of patients treated with immune checkpoint inhibitors
• Patient-level omics data, enriched for endocrine irAE phenotypes—including autoantibodies, germline genetics, and single-cell transcriptomics

Type 1 Diabetes (T1D) Screening and Prevention

We are studying approaches to clinical screening for islet autoantibodies to identify patients at risk and in the early stages of T1D. We study standard of care use of the only FDA approved treatment for early stage T1D, teplizumab, to preserve β-cell function. We also study immunologic and metabolic signatures of disease progression using digital phenotyping, CGM data, and peripheral blood analysis.

Join us

We welcome collaborators and trainees eager to advance endocrine immunology, either in the sphere of cancer immunotherapy or type 1 diabetes.